Edition:
United States

Regeneron Pharmaceuticals Inc (REGN.O)

REGN.O on Nasdaq

296.85USD
16 Aug 2019
Change (% chg)

$3.74 (+1.28%)
Prev Close
$293.11
Open
$295.32
Day's High
$297.35
Day's Low
$290.72
Volume
742,567
Avg. Vol
861,116
52-wk High
$442.00
52-wk Low
$287.66

About

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have... (more)

Overall

Beta: 1.59
Market Cap(Mil.): $50,356.19
Shares Outstanding(Mil.): 107.15
Dividend: --
Yield (%): --

Financials

  REGN.O Industry Sector
P/E (TTM): 47.17 69.38 32.67
EPS (TTM): 9.96 -- --
ROI: 18.73 8.94 14.48
ROE: 24.06 10.07 15.78

Regeneron's Ebola treatment proves superior to rival in trial

Regeneron Pharmaceuticals Inc said on Monday its experimental treatment for Ebola proved superior to a rival therapy from Mapp Biopharmaceutical at preventing death, in a trial evaluating four treatments for infections caused by the deadly virus.

Aug 12 2019

Regeneron's Ebola treatment proves superior to rival in trial

Aug 12 Regeneron Pharmaceuticals Inc said on Monday its experimental treatment for Ebola proved superior to a rival therapy from Mapp Biopharmaceutical at preventing death, in a trial evaluating four treatments for infections caused by the deadly virus.

Aug 12 2019

Regeneron beats second-quarter profit estimates on Eylea boost

Regeneron Pharmaceuticals Inc beat analysts' estimates for second-quarter profit and revenue on Tuesday, boosted by double-digit sales growth of its blockbuster treatment Eylea in the United States.

Aug 06 2019

UPDATE 2-Regeneron beats second-quarter profit estimates on Eylea boost

Aug 6 Regeneron Pharmaceuticals Inc beat analysts' estimates for second-quarter profit and revenue on Tuesday, boosted by double-digit sales growth of its blockbuster treatment Eylea in the United States.

Aug 06 2019

Regeneron second-quarter revenue beats on Eylea sales

Aug 6 Regeneron Pharmaceuticals Inc reported better-than-expected quarterly revenue on Tuesday, boosted by demand for its blockbuster eye drug, Eylea.

Aug 06 2019

French and Benelux stocks-Factors to watch

Aug 6 Below are company-related news and stories from French and Benelux media which could have an impact on the region's markets or individual stocks.

Aug 06 2019

EU approves Sanofi, Regeneron's Dupixent for adolescent eczema cases

PARIS The Dupixent product developed by French healthcare company Sanofi and its U.S. partner Regeneron has won regulatory approval in Europe for moderate-to-severe cases of eczema in adolescents, the companies said.

Aug 06 2019

UPDATE 1-EU approves Sanofi, Regeneron's Dupixent for adolescent eczema cases

PARIS, Aug 6 The Dupixent product developed by French healthcare company Sanofi and its U.S. partner Regeneron has won regulatory approval in Europe for moderate-to-severe cases of eczema in adolescents, the companies said.

Aug 06 2019

EU regulators approve Sanofi, Regeneron's Dupixent for adolescent cases

PARIS, Aug 6 The Dupixent product developed by French healthcare company Sanofi and its U.S. partner Regeneron has won approval in Europe for adolescents with moderate-to-severe atopic dermatitis, the companies said on Tuesday.

Aug 06 2019

REFILE-FDA approves expanded label for Regeneron/Sanofi's Dupixent

June 26 The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals Inc and Sanofi SA's drug Dupixent to treat nasal polyps, the companies said on Wednesday.

Jun 26 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates